MFP-Fluorides for Osteoporosis

(This page last modified 4/10/00)

Recent Scientific Publications


1. R Balens et al: Effects of Different Regimens of Sodium Fluoride Treatment for Osteoporosis on the Structure, Remodeling, and Mineralization of Bone. Osteoporos Int 8:428-35, 1998.
2. BL Riggs et al: Drug Therapy for Vertebral Fractures in Osteoporosis: Evidence that Decreases in Bone Turnover and Increases in Bone Mass Both Determine Antifracture Efficacy. Bone 18(Suppl):197S-201S, 1996.


1. CYC Pak et al: Update of Fluoride in the Treatment of Osteoporosis. The Endocrinologist 8:15-20, 1998.
2. M Kleerekoper: The Role of Fluoride in the Prevention of Osteoporosis. Endocrinol Metab Clin North Am 27:441-52, 1998.
3. FDA Endocrinologic and Metabolic Drugs Advisory Committee Meeting #61, Silver Springs, MD, November 17, 1995. Transcript, 207pp:NDA 19-975 Slow Fluoride (Committee unanimously recommended approval; p.24-bioavailable dosage 9mgF/day)
3a. MG Grodberg: Historical Comment. Ibid, pp. 12-16. 
4. M Kleerekoper: Editorial - Osteoporosis and The Primary Care Physician: Time to Bone Up, Ann Int med 123:466-467, 1995. 
5. National Osteoporosis Foundation: Treatment Update: Osteoporosis Drugs Approved by FDA. Osteoporosis Clinical Updates 1:4, 1995. 
6. CYC Pak et al: Anabolic Effects of Fluoride on Bone. Trends in Endocrinol Metabolism 6:229-234, 1995./Slow-Release Sodium Fluoride in Osteoporosis, J Bone Mineral Research 11:561-564, 1996./Sustained Release Sodium Fluoride in the Management of Established Postmenopausal Osteoporosis. The American Journal of Medical Sciences 313:23-32, 1997. 
7. C Nagant de Deuxchaisnes and JP Devogelaer: Restorative Therapy of Osteopososis (in H. Broll and M.A. Dambacher (eds) - Osteoporosis: A Guide to Diagnosis and Treatment. Rheumatology. Basel-Karger, 1996, vol 18, pp207- 264): Fluoride, pp. 215-264. 
8. DJ Baylink: Slow Release Monofluorophosphate (MFP) As A Bone Formation Stimulant for the Treatment of Established Osteoporosis. (In Symposium on Recent Developments in Osteoporosis Treatment, Annual Meeting of ASBMR, Seattle, WA, September 7, 1996). 
9. E Seeman et al: Present and Future of Osteoporosis Therapy.,  Bone 117, Suppl:235-295, 1995
10. JD Ringe and PJ Meunier:  Editorial--What is the Future for Fluoride in the Treatment of Osteoporosis? Osteoporosis Int. 5:71-74, 1995


1.  JY Reginster et al: The Effect of Sodium Monofluorophosphate plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis: A Randomized Controlled Trial. Ann Intern Med 129:1-8, 1998.
2.  A Battmann et al: Serum Fluoride and Serum Osteocalcin Levels In Response to a Novel Sustained Release Monofluorophosphate Preparation: Comparison with Plain Monofluorophosphate. Osteoporosis Int. 7:48-51, 1997. 
3. CYC Pak et al: Treatment of Postmenopausal Osteoporosis with Slow-Release Sodium Fluoride: Final Report of a Randomized Controlled Trial. Ann Int. Med 123:401-408, 1995. 
4. JE Zerwekh et al: The Effect of Intermittent Slow-Release Sodium Fluoride and Continuous Calcium Citrate Therapy On Calcitropic Hormones, Biochemical Markers of Bone Metabolism and Blood Chemistry In Postmenopausal Osteoporosis. Calcif. Tissue Int. 61:272-278, 1997.
5. CM Schnitzler et al: Fewer Bone Histomorphometric Abnormalities With Intermittent Than Continuous Slow-Release Sodium Fluoride Therapy. Osteoporosis 7:376-389, 1997.
6. JD Adachi et al: FluorIde Therapy In Prevention of Rheumatoid Arthritis Induced Bone Loss. J. Rheumatol. 24:2308-2313, 1997.
7. WF Lems et al: Is Addition of Sodium Fluoride To Cyclical Etidronate Beneficial In The Treatment of Corticorsteroid Induced Osteoporosis? Annals of the Rheumatic Diseases 56:357-363, 1997.
8. J Farrerons et al: Sodium Fluoride Treatment Is a Major Protector Against Vertebral and Fractures When Compared With Other Common Treatments of Osteoporosis: A Longitudinal, Observational Study. Calcif Tissue Int 60:250-254, 1997.

1999 Annual Meeting of American Society for Bone and Mineral Research,St. Louis,MO,September 30-October 4, 1999:Abstracts published in JBMR 14:(Suppl 1) 1999
Senior Author Abstract Number Title
CM Schnitzler F334 Addition of Biphosphonate to Fluoride Therapy Reduces Adverse Fluoride Effects on Bone Quality and Improves Efficacy.
Y-M Li F170 Osteoclast Programmed Cell Death (Apoptosis) In Vitro of Adult Rat:Modulation by Sodium Fluoride In Vivo.

1998 Annual Meeting of American Society for Bone and Mineral Research (held jointly with the International Bone and Mineral Society), San Francisco, CA, December 1-6, 1998: Abstracts published in Bone Vol 23, Number 5S, Nov 1998.
Senior Author Abstract Number Title
K Sakhaee SA 236 A Comparison of Fluoride Bioavailability from Neosten and Other Fluoride Preparations.
AL Negri F 244 Hormone Replacement Therapy with and without Fluoride for Postmenopausal Osteoporosis.
E Vega F 246 Effect of Sodium Monofluorophosphate in Patients with Vertebral Osteopenia.
P Fratzl F 232 Nanostructure and Elasticity of Bone Material after Slow-Release Fluoride Treatment in Osteoporosis.
A Coster F 247 Combined Antiresorptive-Osteoanabolic Treatment of Osteogenesis Imperfecta (OI).
1997 Annual Meeting of American Society for Bone and Mineral Research, Cincinnati, Ohio, September 6-10, 1997: Abstracts published in JBMR 12 (Supplement 1) 1997.
Senior Author Abstract Number Title
CD Rubin T565 Interim Analysis of the Treatment of Senile Osteoporosis Study (TSOS).
JY Reginster 7 Sodium Monofluorophosphate Reduces Vertebral Fractures In Moderate Postmenopausal Osteoporosis.
P Alexandersen 6 Synergistic Effect of Hormone  Replacement Therapy (HRT) Combined with Monofluorophosphate (MFP) on Bone Mass in Late Menopausal Women (published in: J Clin Endocrinol Metab 1999;84:3013-20).
G Ioannidis S641 Fluoride Therapy in the Prevention of Rheumatoid Arthritis Induced Bone Loss.